Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties.

Randall K HooverMartin KršákKyle C MolinaKairav ShahMark Redell

Published in: Open forum infectious diseases (2022)

The new formulation of oritavancin with reduced volume and duration of intravenous infusion demonstrates a safety profile and pharmacokinetics similar to that of the original formulation.

Keyphrases

drug delivery
low dose
high dose